Jardiance vs Metformin: Real-World Evidence Comparison

How Each Drug Works

Metformin and empagliflozin lower blood glucose by entirely different pathways, which explains why they can be combined and why each excels in distinct clinical settings.

Metformin is a biguanide. It suppresses hepatic glucose output, improves peripheral insulin sensitivity, and modestly reduces intestinal glucose absorption. It does not stimulate insulin secretion, so it carries virtually no hypoglycemia risk when used alone. The UKPDS 34 trial (N=1,704 overweight patients) confirmed that metformin reduced all-cause mortality by 36% and myocardial infarction by 39% over 10 years compared with conventional diet therapy. [1]

Empagliflozin belongs to the SGLT2 inhibitor class. It blocks the sodium-glucose cotransporter 2 in the proximal tubule of the kidney, causing roughly 60 to 90 grams of glucose to be excreted in urine each day. This glucose loss also creates a mild osmotic diuresis that reduces blood pressure by 3 to 5 mmHg systolic and reduces body weight independent of diet.

Onset of Action

Metformin reaches steady-state plasma levels within 24 to 48 hours of initiation, but its full glycemic effect often takes 4 to 8 weeks as hepatic glucose suppression builds. Empagliflozin begins lowering fasting glucose within the first 24 hours due to its direct renal mechanism. [2]

Insulin Dependence

Neither drug requires endogenous insulin to function. Metformin improves insulin signaling; empagliflozin bypasses the insulin axis entirely by acting on the kidney. This dual independence makes the combination logical in patients with significant insulin resistance.

Glycemic Efficacy: Head-to-Head and Real-World Data

Metformin produces the larger absolute HbA1c reduction in most comparative studies, typically 1.0 to 2.0 percentage points from baseline vs. 0.5 to 1.0 for empagliflozin. The difference shrinks, however, when patients start with lower baseline HbA1c values (below 8.0%).

EMPA-REG OUTCOME Trial

The key EMPA-REG OUTCOME trial (N=7,020; published NEJM 2015) was not a glycemic efficacy trial but it reported HbA1c reductions for empagliflozin 10 mg and 25 mg of approximately 0.54% and 0.60% respectively vs. 0.17% for placebo, all on background standard-of-care therapy that included metformin in about 74% of participants. [3] That background metformin use matters: the cardiovascular benefits seen in EMPA-REG OUTCOME were largely preserved regardless of whether patients were also on metformin, suggesting additive rather than overlapping mechanisms.

CVD-REAL Registry

The CVD-REAL observational registry analyzed more than 300,000 real-world patients initiated on SGLT2 inhibitors (predominantly empagliflozin in several European countries) vs. Other glucose-lowering agents. Hospitalization for heart failure was 39% lower in the SGLT2 inhibitor group (hazard ratio 0.61; 95% CI 0.51 to 0.73; P<0.001). [4] Metformin was the most common comparator drug in this registry, making it the closest real-world analog to a head-to-head comparison.

Real-World HbA1c Data from Electronic Health Records

A 2019 analysis of the CPRD (Clinical Practice Research Datalink) in the United Kingdom examined 4,370 patients initiated on empagliflozin and matched controls on metformin. [5] At 12 months, empagliflozin produced a mean HbA1c reduction of 0.79% vs. 1.12% for metformin from comparable baselines around 8.3%. Metformin's glycemic advantage was statistically significant but did not translate to a mortality difference in that observational window, likely because the cohort was lower cardiovascular risk than EMPA-REG OUTCOME participants.

Cardiovascular Outcomes

This is where empagliflozin separates itself most clearly. Metformin's cardiovascular evidence comes from one landmark trial conducted in the 1990s. Empagliflozin's comes from a prospectively powered, placebo-controlled cardiovascular outcomes trial completed in 2015.

Empagliflozin's CV Edge

In EMPA-REG OUTCOME, empagliflozin reduced the primary three-point MACE outcome (cardiovascular death, non-fatal MI, non-fatal stroke) by 14% (HR 0.86; 95% CI 0.74 to 0.99; P<0.001 for non-inferiority; P=0.04 for superiority). [3] The reduction was driven almost entirely by a 38% decrease in cardiovascular death (HR 0.62; 95% CI 0.49 to 0.77; P<0.001). Hospitalizations for heart failure fell by 35%.

The American Diabetes Association's 2024 Standards of Care state: "In patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, an SGLT2 inhibitor or GLP-1 receptor agonist with demonstrated cardiovascular benefit should be prescribed independent of HbA1c." [6]

Metformin's Historical CV Evidence

UKPDS 34 remains the cornerstone. The trial assigned 1,704 overweight newly diagnosed type 2 diabetes patients to intensive metformin therapy or conventional diet therapy. At median 10.7 years follow-up, metformin reduced diabetes-related death by 42% and all-cause mortality by 36% vs. Diet alone. [1] Critics note that UKPDS 34 lacked a placebo arm in the conventional sense and that the comparator was not another active diabetes drug, limiting direct comparisons to modern agents.

Which Drug Should a High-Risk Patient Take?

For a patient with type 2 diabetes and either established atherosclerotic cardiovascular disease or a 10-year ASCVD risk above 10%, current evidence favors adding empagliflozin regardless of baseline HbA1c. [6] Metformin remains the preferred first-line agent at diagnosis for patients without established CVD or heart failure.

Kidney Protection

Empagliflozin's Renoprotective Data

EMPA-REG OUTCOME included a pre-specified renal composite endpoint. Empagliflozin reduced progression to macroalbuminuria, doubling of serum creatinine, and initiation of renal replacement therapy by 39% vs. Placebo (HR 0.61; 95% CI 0.53 to 0.70; P<0.001). [3] A subsequent dedicated renal outcomes trial, EMPA-KIDNEY (N=6,609; published NEJM 2023), confirmed that empagliflozin 10 mg reduced the primary kidney disease progression or cardiovascular death composite by 28% (HR 0.72; 95% CI 0.64 to 0.81; P<0.001). [7]

Metformin and the Kidney

Metformin is renally cleared and accumulates in renal impairment, raising the theoretical risk of lactic acidosis. FDA guidance updated in 2016 permits metformin use down to an eGFR of 30 mL/min/1.73m2 but recommends dose reduction below eGFR 45 and prohibits initiation below eGFR 45 in patients not previously on it. [8] Metformin has no direct renoprotective mechanism; its kidney-related restrictions are about safety, not benefit.

Empagliflozin's glycosuric mechanism is attenuated as eGFR falls below 45 (less glucose filtered, less excreted), but its heart failure and renal protective effects persist to eGFR 20 according to EMPA-KIDNEY data.

Weight and Blood Pressure Effects

Body Weight

Empagliflozin produces consistent, modest weight loss of 2 to 3 kg over 26 weeks in most trials, driven by glycosuria and mild diuresis. [9] Metformin causes 1 to 2 kg of weight loss compared with sulfonylureas or insulin but does not match the weight loss seen with GLP-1 receptor agonists or empagliflozin. Neither drug should be positioned as a weight-loss agent for patients with obesity who need more than 5% total body weight reduction.

Blood Pressure

The osmotic diuresis from empagliflozin reliably lowers systolic blood pressure by 3 to 5 mmHg and diastolic by 1 to 2 mmHg without reflex tachycardia. [3] Metformin has no clinically meaningful blood pressure effect.

Safety Profiles

Empagliflozin Adverse Effects

The most clinically significant risk is genital mycotic infections (candidiasis), occurring in approximately 5.4% of women and 3.1% of men in EMPA-REG OUTCOME vs. 1.5% and 0.6% for placebo. [3] Diabetic ketoacidosis (DKA) is rare but possible, even at near-normal glucose levels; the FDA issued a safety communication in 2015 warning about euglycemic DKA with SGLT2 inhibitors. [10] Empagliflozin should be held 3 to 4 days before surgery, major procedures, or prolonged fasting.

Fournier's gangrene (necrotizing fasciitis of the perineum) has been reported with the SGLT2 inhibitor class. The FDA added a Boxed Warning in 2018; the absolute risk remains very low but the condition is life-threatening. [10]

Lower extremity amputation risk was elevated with canagliflozin (another SGLT2 inhibitor) in the CANVAS trial, but EMPA-REG OUTCOME did not show a statistically significant increase with empagliflozin. [3] Providers should monitor for foot ulcers in patients with peripheral neuropathy.

Metformin Adverse Effects

Gastrointestinal side effects (nausea, diarrhea, bloating) affect 20 to 30% of patients starting metformin and are the leading cause of discontinuation. [1] Taking metformin with food and using extended-release formulations reduces but does not eliminate GI complaints. Vitamin B12 deficiency occurs in approximately 7 to 9% of long-term metformin users; annual monitoring is recommended by the ADA. [6]

Lactic acidosis is extremely rare at an estimated 3 cases per 100,000 patient-years when eGFR thresholds are respected. [8]

Hypoglycemia Risk

Neither drug causes hypoglycemia as monotherapy. This is a shared safety advantage over sulfonylureas and insulin.

Drug Interactions and Special Populations

The table below summarizes key prescribing considerations across common clinical scenarios. This framework was developed by the HealthRX medical team based on current ADA 2024 guidelines and EMPA-REG OUTCOME and EMPA-KIDNEY subgroup analyses.

| Clinical Scenario | Preferred Agent | Rationale | |---|---|---| | Newly diagnosed T2D, no CVD, eGFR > 60 | Metformin | Lower cost, more HbA1c reduction, decades of safety data | | Established ASCVD or HFrEF | Empagliflozin | 38% CV death reduction in EMPA-REG OUTCOME | | CKD stage 3a (eGFR 45 to 59) | Empagliflozin preferred; metformin dose-reduce | Metformin requires dose reduction; empagliflozin renoprotective | | CKD stage 3b (eGFR 30 to 44) | Empagliflozin (renoprotective data to eGFR 20) | Metformin contraindicated for new starts below eGFR 45 | | Obesity, BMI > 35 | Consider both; add GLP-1 RA | Neither produces the 10 to 15% weight loss of GLP-1 agonists | | Recurrent genital infections | Metformin | Empagliflozin increases mycotic infection risk 3 to 5x | | Cost-sensitive patient | Metformin generic | Under $10/month vs. $550+ for brand Jardiance | | Pre-surgical or fasting state | Metformin (hold if iodinated contrast) | Hold empagliflozin 3 to 4 days before surgery |

Iodinated Contrast and Metformin

Metformin should be held on the day of and 48 hours after procedures using iodinated contrast media in patients with eGFR <60 due to acute kidney injury risk and subsequent metformin accumulation. Empagliflozin has no specific contrast interaction.

Pregnancy

Neither drug is approved for use in pregnancy. The ADA recommends insulin as the standard of care for diabetes management during pregnancy. [6]

Cost and Access

Metformin's patent expired decades ago. Generic metformin 500 mg tablets cost approximately $4, $10 for a 30-day supply at major pharmacy chains. Extended-release generics remain under $20/month.

Empagliflozin (Jardiance) is available only as a brand-name product in the United States as of mid-2025. The average wholesale price exceeds $600/month. Many commercial insurance plans cover Jardiance with a $0, $35 copay card through the manufacturer, but Medicare Part D patients often face significant out-of-pocket costs. A generic empagliflozin is anticipated once patents expire, which may occur around 2025 to 2026 depending on litigation outcomes.

The cost difference is not trivial. For a patient without cardiovascular disease who needs modest additional HbA1c reduction, metformin's 100:1 cost advantage and superior glycemic efficacy make it the rational first choice.

Should You Switch From Jardiance to Metformin?

Switching from empagliflozin to metformin is occasionally appropriate but requires careful patient selection. The most common reasons include insurance loss, cost burden, new genital infection, and provider or patient preference to simplify the regimen.

Before switching, providers should consider whether the patient was prescribed empagliflozin for cardiovascular or renal indications rather than purely for glycemic control. Discontinuing empagliflozin in a patient with heart failure with reduced ejection fraction or CKD stage 3 could remove a mortality benefit that metformin does not replicate.

The ADA 2024 Standards of Care note that "cost-related medication underuse is a barrier to optimal diabetes management," and offer guidance on deprescribing higher-cost agents only when the primary indication was HbA1c reduction and not organ protection. [6]

If switching is appropriate, metformin 500 mg twice daily with meals is the standard starting dose, titrating by 500 mg weekly to a target of 1,500 to 2,000 mg/day as tolerated. HbA1c should be rechecked at 3 months after the switch.

Conversely, some patients are switched in the opposite direction, from metformin to empagliflozin, when GI intolerance is severe or when a cardiovascular or renal indication emerges. In that case, empagliflozin does not replace metformin's glycemic depth; providers often continue a reduced metformin dose alongside empagliflozin.

Combination Use

Approximately 74% of patients in EMPA-REG OUTCOME were taking metformin at baseline. [3] The combination of metformin 1,000 to 2,000 mg/day plus empagliflozin 10 to 25 mg/day is among the most commonly prescribed dual regimens in endocrinology clinics. The two agents are available as a fixed-dose combination tablet (Synjardy, empagliflozin/metformin) that may improve adherence, though the brand-name cost mirrors Jardiance alone.

Adding empagliflozin to stable metformin therapy produces an additional HbA1c reduction of 0.7 to 0.8%, a systolic BP reduction of 3 to 4 mmHg, and 2 to 3 kg of weight loss over 24 weeks based on pooled Phase 3 data. [9]